DEA Withdraws Immediate Suspension Order Against Morris & Dickson

(May 18, 2018) The Acting Administrator of the DEA announced today that the DEA has rescinded its Immediate Suspension Order (ISO) against Morris & Dickson, LLC (M&D) initiated on May 2. This follows M&D’s successful effort on May 8th to obtain a court order preventing DEA from enforcing the ISO. The DEA was set to appear in court next Tuesday to try to have the ISO reinstated but is abandoning that effort.

This unprecedented reversal means that M&D will continue to fully and capably serve its customers, providing the full range of products that they and their patients need.

“This is a striking vindication for our family company,” said Paul Dickson, President of M&D. “This proves what we’ve said all along— that DEA’s hasty action was unjustified.  We have always taken our responsibility to prevent diversion seriously.”

“But we’re not resting on our record of no enforcement action in 177 years. We are enhancing our suspicious order monitoring into what will be recognized as a state-of-the-art diversion control system. This project is already underway and is headed by Louis Milione, former DEA Director of Diversion as well as the Analysis Group, whose experts have developed suspicious order monitoring algorithms for DEA registrants. We look forward to working with the DEA and other critical members of the healthcare community on model drug diversion control and patient safety measures.”

Background Facts:

  • M&D has never before faced any DEA enforcement action, fine, or penalty in its 177 year history.
  • M&D has had sound internal controls that have reduced M&D’s opioid distribution by 27% since 2014.
  • M&D has voluntarily turned away over 142 paying pharmacies in recent years to avoid the improper distribution of opioids, representing an 8% total reduction of its customer base. The DEA had no involvement in identifying any of those cases.
  • In 2016, M&D invited top DEA Diversion Control officials to personally visit and review its control procedures, which they did. The company asked for suggested improvements but got none.
  • On numerous occasions, M&D has offered to demonstrate to the DEA how it can more effectively use existing private sector technology and data to identify instances of opioid diversion and abuse.